Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001082

Drug Information
NameVorinostat
SynonymsZINC01543873; NSC701852; UNII-58IFB293JI; N-Hyrdroxy-N'-phenyloctanediamide; Vorinostat; N-hydroxy-N'-phenyloctanediamide; Merck brand of Vorinostat; WIN64652; Vorinostat [USAN]; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; NSC-701852; NHNPODA; Zolinza; m344; SAHA, Suberoylanilide hydroxamic acid; N-Hydroxy-N'-phenyl octanediamide; SMR000486344; Zolinza (TN); CID5311; CHEMBL98; Zolinza, MK-0683, SAHA; S1047_Selleck; suberoylanilide hydroxamic acid; nchembio815-comp18; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; D06320; SKI390; LS-187780; AC-1923; N'-hydroxy-N-phenyloctanediamide; EC-000.2057; CCRIS 8456; nchembio.275-comp2; 1zz1; MLS001065855; MK0683; SHH; N1-hydroxy-N8-phenyloctanediamide; SAHA; LS-186997; NCGC00168085-02; MK-0683; SAHA cpd; AC1L1K2K; Vorinostat MSD; C111237; LS-186548; Suberanilohydroxamic acid; Octanediamide, N-hydroxy-N'-phenyl-; Vorinostat (JAN/USAN); FT-0082592; CHEBI:45716; SW-064652; DB02546; nchembio.313-comp1; MolPort-003-850-293; BRD-K81418486-001-10-3; 149647-78-9
Trade NameZolinza
CompanyMerck & Co., Inc.
IndicationCutaneous T-cell lymphoma
[ICD9: 202.1, 202.2   ICD10: C84.0, C84.1]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19
/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
InChIKeyWAEXFXRVDQXREF-UHFFFAOYSA-N
Canonical SMILESC1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 149647-78-9
FormulaC14H20N2O3
PubChem Compound IDCID 5311.
PubChem Substance IDSID 730694.
SuperDrug ATC IDL01XX38
L01XX38
TargetHistone deacetylase 1Inhibitor[2][3][4]
Ref 1Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. To Reference
Ref 2Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. To Reference
Ref 3Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. J Med Chem. 2009 Jun 11;52(11):3453-6. To Reference
Ref 4Nat Rev Drug Discov. 2006 Sep;5(9):769-84.Anticancer activities of histone deacetylase inhibitors. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543